Last updated: July 31, 2026
Indium In-111 pentetreotide, marketed historically as OctreoScan, is an FDA-approved diagnostic radiopharmaceutical for scintigraphic localization of somatostatin receptor-positive neuroendocrine tumors and other receptor-expressing lesions. Its clinical role has contracted sharply because gallium-68 and copper-64 somatostatin-receptor PET agents provide higher-resolution imaging, shorter procedures and better integration with modern neuroendocrine tumor care. The commercial outlook for the In-111 kit is therefore declining, with residual demand concentrated in institutions that lack PET access, use legacy imaging protocols or require SPECT-based localization.
What is indium In-111 pentetreotide used for?
Indium In-111 pentetreotide is a radiolabeled somatostatin analog. After intravenous administration, the compound binds primarily to somatostatin receptor subtype 2, allowing imaging with a gamma camera or SPECT system.
The FDA labeling identifies the principal use as localization of primary and metastatic somatostatin-receptor-positive neuroendocrine tumors, including carcinoid tumors. The agent has also been used to localize pituitary adenomas and other receptor-positive lesions, although clinical use depends on institutional protocols and the availability of more advanced PET agents.[1]
Product and administration profile
| Attribute |
Indium In-111 pentetreotide |
| Product type |
Radiolabeled diagnostic kit |
| Historical brand |
OctreoScan |
| Radionuclide |
Indium-111 |
| Imaging modality |
Planar scintigraphy and SPECT |
| Target |
Somatostatin receptors, principally SSTR2 |
| Administration |
Intravenous |
| Typical imaging |
Early and delayed imaging, often including 24-hour views |
| Primary disease area |
Neuroendocrine tumors |
| Regulatory status |
FDA-approved diagnostic radiopharmaceutical |
| Main substitutes |
Ga-68 DOTATATE, Ga-68 DOTATOC, Cu-64 DOTATATE |
The kit is reconstituted and radiolabeled with indium-111 chloride before administration. Nuclear pharmacies and radiopharmacy providers must manage radionuclide supply, time-sensitive preparation, quality control, radiation safety and distribution logistics.
What is the FDA regulatory status of OctreoScan and indium In-111 pentetreotide?
The FDA approved OctreoScan under NDA 019793 in 1994. The product’s regulatory position is mature rather than developmental. It is not a new molecular entity and does not have an active clinical development program comparable with modern PET somatostatin-receptor agents.[1]
The primary regulatory issue is commercial availability. Radiopharmaceutical listings can change as manufacturers discontinue products, transfer rights or revise distribution arrangements. The FDA’s Drugs@FDA database and current manufacturer labeling remain the controlling sources for active product status, approved labeling and any discontinuation record.[2]
What is the Orange Book status?
Indium In-111 pentetreotide is an older diagnostic product whose commercial protection is materially different from that of a conventional small-molecule prescription drug. The relevant barriers are generally:
- Manufacturing and radiopharmacy validation
- Access to indium-111 chloride
- FDA-approved kit and labeling
- Product-specific quality systems
- Nuclear pharmacy distribution
- Hospital and imaging-center purchasing contracts
- Reimbursement and procedure-code economics
The commercial value of any listed patent is limited if the core product has no meaningful remaining patent term. For an approval dating to 1994, any original composition or formulation patents would ordinarily have expired or approached expiration long ago, subject to patent-specific adjustments.
Are there active clinical trials for indium In-111 pentetreotide?
Indium In-111 pentetreotide is primarily a legacy imaging agent in clinical research. Current neuroendocrine tumor trials more often use Ga-68 DOTATATE, Ga-68 DOTATOC, Cu-64 DOTATATE or therapeutic radioligands such as lutetium-177 oxodotreotide.
ClinicalTrials.gov contains historical studies involving In-111 pentetreotide, including studies evaluating somatostatin-receptor imaging, neuroendocrine tumors, pituitary disease and comparison with other diagnostic techniques. The agent is unlikely to generate substantial new interventional-trial activity because the clinical development focus has shifted toward PET imaging and theranostic treatment selection.[3]
Clinical-trial relevance by use case
| Use case |
Current role of In-111 pentetreotide |
Development direction |
| Neuroendocrine tumor localization |
Legacy or access-constrained use |
Ga-68 and Cu-64 PET |
| SSTR expression assessment |
Limited |
PET-based receptor imaging |
| Peptide receptor radionuclide therapy selection |
Historical support |
Ga-68 DOTATATE and Cu-64 DOTATATE |
| Pituitary adenoma imaging |
Niche |
MRI, PET and receptor-specific imaging |
| Comparative diagnostic studies |
Low activity |
PET versus conventional imaging |
| New therapeutic development |
Minimal |
Lu-177 and Ac-225 radioligand programs |
The most important clinical development trend is substitution. The FDA approved Netspot, a Ga-68 DOTATATE injection, in 2016 and Detectnet, a Cu-64 DOTATATE injection, in 2020. These agents target the same general receptor biology but use PET, which provides higher sensitivity, improved spatial resolution and faster image acquisition than conventional In-111 SPECT imaging.[4][5]
How does indium In-111 pentetreotide compare with Ga-68 DOTATATE and Cu-64 DOTATATE?
| Factor |
In-111 pentetreotide |
Ga-68 DOTATATE |
Cu-64 DOTATATE |
| Imaging platform |
SPECT |
PET |
PET |
| FDA approval |
1994 |
2016 |
2020 |
| Image resolution |
Lower |
Higher |
Higher |
| Imaging schedule |
Delayed imaging commonly required |
Same-day PET |
Flexible same-day imaging |
| Distribution logistics |
Kit plus In-111 chloride |
Generator or centralized production |
Cyclotron or centralized production |
| Current clinical momentum |
Declining |
Strong |
Growing |
| Theranostic integration |
Limited |
Strong with Lu-177 programs |
Strong |
| Competitive risk |
High |
Benchmark product |
Expanding alternative |
Ga-68 DOTATATE has the strongest displacement effect because it is widely recognized as a preferred PET imaging option for well-differentiated neuroendocrine tumors. Cu-64 DOTATATE offers a longer physical half-life than Ga-68, which can support broader distribution and more flexible scheduling. The choice depends on local PET capacity, isotope supply, reimbursement, clinical protocol and institutional preference.
What patents protect indium In-111 pentetreotide?
The core commercial product is exposed to substantial patent-age pressure. The active ingredient, pentetreotide, is an established somatostatin analog, and the radiolabeled diagnostic product was approved decades ago. Core composition, labeling and basic formulation patents associated with the original product would not ordinarily provide meaningful exclusivity in 2025.
Remaining intellectual-property barriers
The practical IP position is more likely to involve operational know-how than blocking patent rights:
- Kit formulation and stabilizer selection
- Radiolabeling conditions and quality-control specifications
- Sterility and radiochemical-purity procedures
- Packaging for short-lived radionuclide distribution
- Manufacturing scale and release testing
- Regulatory documentation and validated processes
A later entrant could still face development costs and regulatory risk, but a robust, long-lived composition-of-matter patent estate is unlikely to protect the original product at this stage.
Are there Paragraph IV challenges?
No major, commercially significant Paragraph IV litigation campaign involving indium In-111 pentetreotide is widely associated with the current market. The product’s age, limited market size and shrinking clinical demand reduce the incentive for a conventional generic challenge.
The more relevant entry scenario is an approved competing kit or radiopharmacy product supported by manufacturing capability, not a high-value Hatch-Waxman challenge designed to capture a large branded prescription market.
What is the market size and commercial outlook?
Public financial disclosures generally do not report standalone revenue for indium In-111 pentetreotide. Revenue is typically aggregated within nuclear medicine, diagnostic imaging or radiopharmaceutical segments. A product-specific market size therefore cannot be established from issuer filings alone.
The market is structurally declining for four reasons:
- PET substitution by Ga-68 and Cu-64 agents
- Greater availability of PET/CT systems
- Clinical preference for receptor imaging with higher sensitivity
- Reduced role in theranostic patient selection
2025-2030 market projection
The following scenario reflects the product’s mature and declining position relative to SSTR PET imaging.
| Year |
Relative market index, 2025 = 100 |
Estimated annual trend |
Primary driver |
| 2025 |
100 |
Baseline |
Residual SPECT demand |
| 2026 |
90-95 |
-5% to -10% |
PET substitution |
| 2027 |
81-90 |
-5% to -10% |
Wider Ga-68 and Cu-64 access |
| 2028 |
73-86 |
-5% to -10% |
Protocol conversion |
| 2029 |
66-82 |
-5% to -10% |
Institutional migration to PET |
| 2030 |
59-78 |
-5% to -10% |
Niche and access-constrained use |
The decline is likely to be slower in hospitals without reliable PET access, in regions with constrained isotope supply and in markets where reimbursement favors SPECT. It is likely to be faster in major cancer centers with established neuroendocrine tumor programs.
Which companies compete with indium In-111 pentetreotide?
The principal competitive products are not direct In-111 kit equivalents. They are receptor-targeted PET products and related radiopharmaceutical services.
| Company or product |
Product |
Competitive position |
| Curium or legacy OctreoScan supply chain |
In-111 pentetreotide |
Mature SPECT product |
| Advanced Accelerator Applications, a Novartis company |
Netspot, Ga-68 DOTATATE |
Established SSTR PET competitor |
| RadioMedix and Curium |
Detectnet, Cu-64 DOTATATE |
Longer-lived PET alternative |
| Nuclear pharmacies and regional radiopharmacies |
Compounded or distributed diagnostic radiopharmaceuticals |
Local supply and access competition |
| Academic and hospital radiopharmacies |
Institutional production or distribution |
Important in constrained markets |
The relevant competitive metric is installed PET capacity and isotope access, not simply the number of manufacturers selling In-111 kits.
What generic launch risks exist?
A new entrant would face moderate regulatory and manufacturing risk but limited market upside.
Main entry barriers
- FDA requirements for kit manufacturing and radiochemical quality
- Reliable In-111 chloride supply
- Short product shelf life
- Radiopharmacy distribution infrastructure
- Radiation-safety compliance
- Need for hospital protocol adoption
- Reimbursement pressure
- Physician migration to PET
Generic launch scenarios
| Scenario |
Probability profile |
Commercial result |
| No material new entrant |
Most likely |
Continued decline of legacy supply |
| One regional supplier enters |
Plausible |
Price competition in SPECT-dependent markets |
| Broad U.S. generic launch |
Less attractive |
Limited share because of PET substitution |
| International niche launch |
Plausible |
Demand in markets with limited PET access |
| Product withdrawal |
Possible |
Accelerated conversion to PET or supply gaps |
What patent litigation and settlement activity affects the product?
There is no major current patent dispute that appears to define the commercial outlook for In-111 pentetreotide. The material legal risks are more likely to involve product availability, labeling, manufacturing compliance, procurement contracts or reimbursement than patent infringement.
Settlement agreements also have limited strategic relevance because the product’s commercial value is declining and no major exclusivity dispute is apparent. The strongest competitive protection belongs to newer PET products through their own regulatory, manufacturing and commercial infrastructure rather than through continued exclusivity for In-111 pentetreotide.
How strong is the patent estate for indium In-111 pentetreotide?
The estate is weak as a current commercial moat. Its principal strengths are historical regulatory approval, physician familiarity and existing nuclear medicine workflows. Its principal weaknesses are product age, technological displacement and the absence of a meaningful remaining composition-of-matter exclusivity period.
| Patent-estate factor |
Assessment |
| Core molecule protection |
Weak or expired |
| Original product protection |
Mature and likely expired |
| Formulation protection |
Limited current value |
| Method-of-use protection |
Narrow and clinically displaced |
| Manufacturing know-how |
Relevant but nonexclusive |
| Regulatory moat |
Moderate |
| Distribution moat |
Moderate to strong locally |
| Long-term commercial durability |
Low |
Key Takeaways
- Indium In-111 pentetreotide is a mature SPECT radiopharmaceutical with declining clinical use.
- OctreoScan was FDA-approved in 1994 for imaging somatostatin-receptor-positive tumors.
- Ga-68 DOTATATE and Cu-64 DOTATATE are the main substitutes and have stronger clinical momentum.
- Current clinical-trial activity is limited and largely historical.
- No major active Paragraph IV or patent-litigation campaign defines the product’s market.
- Core patent protection is unlikely to provide a meaningful current exclusivity barrier.
- The 2025-2030 market is expected to contract at approximately 5% to 10% annually under a base-case substitution scenario.
- Residual demand will remain in SPECT-dependent institutions and regions with limited PET access.
- The main commercial risk is loss of clinical relevance, not generic competition.
FAQs
Is indium In-111 pentetreotide still used for neuroendocrine tumors?
Yes. It remains available in selected settings, but PET agents such as Ga-68 DOTATATE and Cu-64 DOTATATE have displaced it in many major centers.
Is OctreoScan the same as indium In-111 pentetreotide?
Yes. OctreoScan is the historical brand associated with indium In-111 pentetreotide imaging.
Can indium In-111 pentetreotide be used for peptide receptor radionuclide therapy?
It has historical value for demonstrating somatostatin-receptor expression, but modern treatment selection generally uses SSTR PET imaging.
Does indium In-111 pentetreotide have biosimilar competition?
No. Biosimilar rules apply to biologic products. This is a radiolabeled diagnostic small-molecule product, so the relevant competition is generic, kit-based or radiopharmacy-based.
What is the main investment risk for indium In-111 pentetreotide?
The primary risk is continued substitution by PET-based somatostatin-receptor imaging, which can reduce procedure volume even if the legacy product remains technically approved and commercially available.
References
- U.S. Food and Drug Administration. (1994). OctreoScan (indium In-111 pentetreotide) prescribing information.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/
- National Library of Medicine. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/
- U.S. Food and Drug Administration. (2016). Netspot (gallium Ga-68 dotatate) prescribing information.
- U.S. Food and Drug Administration. (2020). Detectnet (copper Cu-64 dotatate) prescribing information.
